AngioDynamics Company Profile (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Tuesday, July, 18th. The company reported $0.19 EPS for the quarter, topping the Zacks' consensus estimate of $0.16 by $0.03. The business had revenue of $86.90 million for the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a negative net margin of 14.86% and a negative return on equity of 9.90%. The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period last year, the company posted $0.19 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Thursday, September, 28th 2017. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY18 earnings guidance on Tuesday, July, 18th. The company provided EPS guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $357.75 million.

5 brokerages have issued 12 month price targets for AngioDynamics' shares. Their predictions range from $16.00 to $21.00. On average, they anticipate AngioDynamics' stock price to reach $18.50 in the next year. View Analyst Ratings for AngioDynamics.

Here are some recent quotes from research analysts about AngioDynamics stock:

• 1. According to Zacks Investment Research, "AngioDynamics reported a mixed fourth quarter of fiscal 2017, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. The year-over-year decline at the company’s Peripheral Vascular, Vascular Access and Oncology & Surgery business segments marred revenues. Furthermore, the company expects earnings to fall sequentially in FY18. Lackluster performance by the oncology segment was primarily due to market withdrawal of the company’s flagship Acculis Microwave Tissue Ablation System, which also marred international sales. AngioDynamics has a high outstanding debt level at the end of the fourth quarter. This is likely to impose certain operating and financial restrictions, limiting the company’s core business strategies. Over the last one year, AngioDynamics has underperformed the broader industry in terms of price. However, growth in the core Angiographic Catheter business holds promise." (8/14/2017)
• 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)

Some companies that are related to AngioDynamics include TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Genus plc (GNS), Knight Therapeutics (GUD), Knight Therapeutics (GUD), Clinigen Group PLC (CLIN), ProMetic Life Sciences (PLI), Asante Solutions (PUMP), Genomic Health (GHDX), The Ensign Group (ENSG), Arena Pharmaceuticals (ARNA), Spire Healthcare Group PLC (SPI), National HealthCare (NHC), Canfor Pulp Products (CFX), Extendicare (EXE), Novadaq Technologies (NDQ) and CVS Group Plc (CVSG).

AngioDynamics' management team includes the folowing people:

• Howard W. Donnelly, Independent Chairman of the Board
• James C. Clemmer, President, Chief Executive Officer, Director
• Michael Greiner, Chief Financial Officer, Executive Vice President
• Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
• Ben Davis, Senior Vice President, Business Development
• Barbara Kucharczyk, Senior Vice President-Global Operations
• Stephen A. Trowbridge, Senior Vice President, General Counsel
• Eileen O'Shea Auen, Director
• Jan Stern Reed, Director
• David F. Burgstahler, Independent Director

AngioDynamics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (8.50%), Vanguard Group Inc. (5.29%), Broadfin Capital LLC (4.60%), Northern Trust Corp (3.28%), Wells Fargo & Company MN (2.77%) and Janus Henderson Group PLC (2.63%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler, James C Clemmer, Jan Stern Reed and Stephen A Trowbridge. View Institutional Ownership Trends for AngioDynamics.

AngioDynamics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Numeric Investors LLC, Russell Investments Group Ltd., FMR LLC, Acadian Asset Management LLC, Cornerstone Capital Management Holdings LLC., Systematic Financial Management LP and Algert Global LLC. View Insider Buying and Selling for AngioDynamics.

AngioDynamics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Peregrine Capital Management LLC, Wells Fargo & Company MN, Marshall Wace North America L.P., Vanguard Group Inc., Broadfin Capital LLC, Great Lakes Advisors LLC and Northern Trust Corp. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.

Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AngioDynamics stock can currently be purchased for approximately $17.95.